Section Arrow
PULM.NASDAQ
- Pulmatrix
Quotes are at least 15-min delayed:2025/06/01 01:51 EDT
Last
 8.98
+0.78 (+9.51%)
Day High 
Prev. Close
8.2 
1-M High
9.37 
Volume 
33.16K 
Bid
3.52
Ask
9
Day Low
8.05 
Open
8.3 
1-M Low
5.88 
Market Cap 
29.95M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 7.04 
20-SMA 6.66 
50-SMA 6.47 
52-W High 10.4 
52-W Low 1.78 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.62/-2.24
Enterprise Value
29.95M
Balance Sheet
Book Value Per Share
1.96
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
7.81M
Operating Revenue Per Share
1.90
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
INABIN8bio0.1446-0.0088-5.74%-- 
BLRXBioLineRx Ltd5.18+1.3891+36.64%-- 
IMNNImunon2.45+0.46+23.12%-- 
NCNANuCana plc0.03525-0.00175-4.73%-- 
MRNAModerna26.58-0.35-1.30%-- 
Quotes are at least 15-min delayed:2025/06/01 01:51 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.